[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
We have treated 8 patients with metastatic renal cell carcinoma for whom prior immunotherapy proved uneffective. The patients consisted of 6 males and 2 females, with a median age of 68 years. One patient had a primary site in place and 5 patients had multiple organs involvement. The chemotherapy consisted of gemcitabine 1,000 mg/m(2) div at day 1, 8 and capecitabine 1,657 mg/m(2)/day p.o. at day 1-14, followed by a week rest period. Then, the regimen was repeated every 3 weeks. No treatment response was observed. There were two SD, three SD to PD, and two PD after a median of 3 cycles of treatment. The median time to disease progression was 9.1 months, and the one-year progression- free survival rate was 83%. Adverse effects were observed in 3 cases (37.5%), however, treatment was well tolerated. Despite the limited anti-tumor efficacy, it would be meaningful that the treatment brought disease stabilization to the majority of this group of patients.